Objective To explore effects of Zhima Xiaotan Huoxue Recipe on no-reflow and prognosis after percutaneous coronary intervention(PCI) in low-risk non-ST-elevation acute coronary syndrome(NSTE-ACS) patients and its possible action mechanism.
Methods A total of 72 low-risk NSTE-ACS patients who underwent elective PCI were selected as objects and randomly divided into control group and experimental group. A total of 36 patients in the control group were given conventional treatment and nursing by western medicine, and the experimental group orally administrated Zhima Xiaotan Huoxue Decoction 7 days before the operation based on the control group. The blood flow grading (TIMI) after operation, the incidence of no-reflow phenomenon, blood flow grading of TIMI myocardial perfusion grade (TMPG), and incidence of major adverse cardiac events (MACE), left ventricular ejection fraction (LVEF) and N-terminal precursor B type natriuretic peptide (NT-proBNP) 7 days and 30 days after surgery, interleukin (IL)-2, IL-6, hypersensitive C-reactive protein (hs-CRP) and endothelial glycocalyx degradation products heparan, Syndecan-1, hyaluronic acid levels were compared.
Results After the intervention, the proportions of patients with TIMI 3 and TMPG 3 and postoperative LVEF levels in the experimental group were higher than those in the control group (P < 0.05); after intervention, the incidence of no-reflow, postoperative NT-proBNP, IL-2, IL-6, hs-CRP, serum heparan sulfate, Syndecan-1, and hyaluronic acid levels in the experimental group were lower than those of the control group (P < 0.01).
Conclusion Zhima Xiaotan Huoxue Decoction can effectively prevent the occurrence of no-reflow after the low-risk NSTE-ACS after PCI, increase myocardial blood perfusion, reduce the total incidence of MACE, inhibit inflammation, relieve vascular endothelial damage, and improve cardiac function and prognosis.
DownLoad: